We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Compugen Ltd | NASDAQ:CGEN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.05 | -2.31% | 2.11 | 2.08 | 2.22 | 2.22 | 2.065 | 2.22 | 231,334 | 01:00:00 |
From May 2019 to May 2024
By Colin Kellaher
Bristol-Myers Squibb Co. (BMY) and Compugen Ltd. (CGEN) Thursday said they will evaluate the safety and tolerability of Compugen's COM701 antibody in combination with Bristol-Myers' cancer drug Opdivo in patients with advanced solid tumors.
As part of the collaboration, Bristol-Myers will invest $12 million in Compugen, buying 2.42 million shares of the Israel-based therapeutic discovery and development company at $4.95 apiece. Compugen shares, which closed Wednesday at $3.25, surged 17% to $3.80 in premarket trading Thursday.
The companies said Compugen will sponsor an ongoing two-part Phase 1 trial that includes evaluating the combination of COM701 and Opdivo in four tumor types, including non-small cell lung, ovarian, breast and endometrial cancer. The collaboration is also designed to address potential future combinations, including trials sponsored by Bristol-Myers, the companies said.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 11, 2018 07:35 ET (11:35 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Compugen Chart |
1 Month Compugen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
